

## PEER REVIEW HISTORY

BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (<http://bmjopen.bmj.com/site/about/resources/checklist.pdf>) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.

### ARTICLE DETAILS

<b>TITLE (PROVISIONAL)</b>	Cohort profile: The LipidCardio Study - Role of Lipoproteins in Cardiovascular Disease
<b>AUTHORS</b>	König, Maximilian; Joshi, Samita; Leistner, David; Landmesser, U; Sinning, David; Steinhagen-Thiessen, Elisabeth; Demuth, Ilja

### VERSION 1 – REVIEW

<b>REVIEWER</b>	Fabrizio D'Ascenzo San Giovanni Battista Molinette, Italy
<b>REVIEW RETURNED</b>	09-Apr-2019

<b>GENERAL COMMENTS</b>	<p>the present is an interesting sub analysis of the cohort study aiming to evalaute the role of lipoprotein and its correlation with obstructive CAD.</p> <p>Some issues should be related:</p> <ul style="list-style-type: none"> <li>- in the abstract indication for PCI (stable vs.ACS) should be added</li> <li>- it should be added if the relationship of lipoprotein with obstructive cad was valuated at multivariate analysis or not</li> <li>- introduction should be shortened to at least 1 page</li> <li>- differences in lipoprotein and genetic should be added</li> <li>- impact of long term dapt remains an important issue along with kind of dapt. if possible analysis for lenght of dapt should be added and discussed (quote on PMID: 30862233)</li> </ul>
-------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### VERSION 1 – AUTHOR RESPONSE

Reviewer's Comments to Author:

Reviewer: 1

Reviewer Name: Fabrizio D'Ascenzo

Institution and Country: San Giovanni Battista Molinette, Italy Please state any competing interests or state 'None declared': None declared

the present is an interesting sub analysis of the cohort study aiming to evalaute the role of lipoprotein and its correlation with obstructive CAD.

Some issues should be related:

- in the abstract indication for PCI (stable vs.ACS) should be added

Thanks for this important remark. We have now added "troponin-positive coronary syndrome was exclusion criterion" in the abstract.

- it should be added if the relationship of lipoprotein with obstructive cad was valued at multivariate analysis or not

We have now specified the odds ratio as “crude OR”, to indicate that the association was not examined in a multivariable/multivariate analysis.

- introduction should be shortened to at least 1 page

We agree that the introduction was a bit lengthy. We have revised it now, and it is significantly shorter now (about half page less). However, we would be reluctant to shorten it further, since the rationale of the study needs to be properly explained.

- differences in lipoprotein and genetic should be added

As we see it the article-type “cohort profile” is not designed to include a discussion. That is why we have not discussed that/why serum Lp(a) is more strongly associated with CAD than LPA-SNPs - which is a common finding. Please see the excellent review on this topic:

Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Kronenberg F., Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):5-12. doi: 10.1007/s11789-019-00093-5. PMID: 30859385

Anyway, we have stated both associations clearly, and also indicated that the evidence for the association CAD – LPA-SNPs was rather weak, and that there was interaction with sex.

- impact of long term dapt remains an important issue along with kind of dapt. if possible analysis for length of dapt should be added and discussed (quote on PMID: 30862233)

We have gathered information on type of platelet aggregation inhibitor used at the time of enrolment. We will retrieve platelet aggregation inhibitor use at the follow-up phone-calls. This will allow us to analyse the effect of type and length of use on disease progression/recurrent vascular events. In this “cohort-profile” we don’t have longitudinal data yet.